Pulmonx
Terry Solomon, PhD, is a Senior Regulatory Affairs Specialist at Pulmonx Corporation since October 2019, after previously serving as a Regulatory Affairs Specialist at Natera. Experience includes conducting annual reviews of CE Technical Files and implementing projects for IVDR compliance. Terry completed a PhD in Biomedical Sciences at UC San Diego, focusing on genetic variants related to serum and plasma protein levels, and has held various roles in consulting and research, including leading a project team at the Advanced Professional Degree Consulting Club. Additional research experience includes work on age-related hearing loss at Rochester Institute of Technology and an internship at the Max Planck Institute for Evolutionary Biology. Terry possesses a Specialized Certificate in Regulatory Affairs and a Bachelor of Science in Biomedical Sciences and Biotechnology.
This person is not in any teams
Pulmonx
2 followers
Pulmonx has developed the Zephyr Endobronchial Valve, a minimally invasive treatment for COPD/emphysema. The one-time procedure is done by bronchoscopy and requires no cutting or incisions. During the procedure, on average 4 tiny valves are placed in the airways to block off the diseased parts of the lung which allows trapped air to escape until the lobe is reduced. Reducing hyperinflation allows the healthier parts of the lungs to expand and take in more air. This results in patients being able to breathe easier and have less shortness of breath.1